NextCure Inc. (NXTC)
0.41
0.01 (2.37%)
At close: Apr 23, 2025, 2:17 PM
2.37% (1D)
| Bid | 0.29 |
| Market Cap | 11.55M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -55.65M |
| EPS (ttm) | -1.99 |
| PE Ratio (ttm) | -0.21 |
| Forward PE | -0.23 |
| Analyst | Buy |
| Ask | 0.53 |
| Volume | 144,291 |
| Avg. Volume (20D) | 128,013 |
| Open | 0.41 |
| Previous Close | 0.40 |
| Day's Range | 0.41 - 0.42 |
| 52-Week Range | 0.22 - 1.82 |
| Beta | 0.89 |
About NXTC
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune sup...
Industry Biotechnology
Sector Healthcare
IPO Date May 9, 2019
Employees 43
Stock Exchange NASDAQ
Ticker Symbol NXTC
Website https://www.nextcure.com
Analyst Forecast
According to 2 analyst ratings, the average rating for NXTC stock is "Buy." The 12-month stock price forecast is $3.5, which is an increase of 748.48% from the latest price.
Stock Forecasts5 months ago
+1.55%
NextCure shares are trading higher after the compa...
Unlock content with
Pro Subscription
7 months ago
-5%
NextCure shares are trading lower. The company announced results from its Phase 1b study of NC410.
